Diego Bellido - semaglutida alzhimer Diego Bellido Head of the Endocrinology and Nutrition Department at the Ferrol Hospital Complex (CHUF) and President of the Spanish Society for Obesity (SEEDO) Does the press release accurately reflect the study
Two clinical trials were done on semaglutide and Alzheimers, and they did not show any benefits, Low Wang said
Both semaglutide and tirzepatide have been approved by major regulatory authorities following extensive clinical research
Before starting Rybelsus alongside omeprazole, or if you are already taking both medications, several important points warrant discussion with your GP, diabetes specialist nurse, or pharmacist : Medication review: Confirm that omeprazole remains clinically indicatedPPIs are sometimes continued longer than necessary Discuss whether your omeprazole dose could be reduced or whether intermittent (on-demand) use might be appropriate Review all other medications for potential interactions or timing conflicts Consider whether any medications could be switched to evening dosing to simplify your morning routine Monitoring glycaemic control: Establish a plan for regular blood glucose monitoring, particularly when initiating Rybelsus Discuss target HbA1c levels and how frequently this should be checked (typically every 36 months per NICE guidance) Report any unexplained hyperglycaemia, as this may indicate absorption issues Keep a record of your readings to identify patterns Gastrointestinal symptoms: Rybelsus commonly causes nausea, vomiting, diarrhoea, and abdominal discomfort , particularly during dose escalation Distinguish between Rybelsus-related GI side effects and symptoms requiring PPI therapy If reflux symptoms worsen, this may be coincidental or related to delayed gastric emptying (a GLP-1 effect) Persistent or severe GI symptoms warrant medical review Practical adherence support: Discuss strategies to remember the 30-minute waiting period Explore whether your lifestyle or work pattern makes Rybelsus adherence difficult Ask about alternative GLP-1 therapies (such as once-weekly subcutaneous semaglutide) if oral administration proves problematic If also taking insulin or sulphonylureas, discuss potential dose adjustments to reduce hypoglycaemia risk Red flag symptoms requiring urgent medical attention include severe abdominal pain (possible pancreatitis), persistent vomiting with inability to retain fluids, right upper abdominal pain with fever or jaundice (possible gallbladder disease), sudden vision changes (potential retinopathy complications), or signs of hypoglycaemia if taking Rybelsus with insulin or sulphonylureas
